Trenbolone hexahydrobenzylcarbonate
Clinical data | |
---|---|
Trade names | Parabolan, Hexabolan |
Other names | Trenbolone cyclohexylmethylcarbonate; Estra-4,9,11-trien-17β-ol-3-one 17β-cyclohexylmethylcarbonate |
Routes of administration | Intramuscular injection |
Drug class | Androgen; Anabolic steroid; Androgen ester; Progestogen |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.041.503 |
Chemical and physical data | |
Formula | C26H34O4 |
Molar mass | 410.554 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Trenbolone hexahydrobenzylcarbonate, or trenbolone cyclohexylmethylcarbonate, sold under the brand names Parabolan and Hexabolan, is a synthetic, injected anabolic–androgenic steroid (AAS) of the nandrolone group and an androgen ester – specifically, the C17β hexahydrobenzylcarbonate (cyclohexylmethylcarbonate) ester of trenbolone – which was marketed in France for medical use in humans but has since been discontinued.[1]
It was introduced in France in 1980 and was voluntarily discontinued by its manufacturer in 1997.[1][2] The drug acts as a long-lasting prodrug of trenbolone when administered via intramuscular injection.[1] It was used clinically at a dosage of one ampoule (76 mg, corresponding to 50 mg trenbolone base) every 10 days.[1]
See also
References
Further reading
- Yarrow JF, McCoy SC, Borst SE (2010). "Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity". Steroids. 75 (6): 377–89. doi:10.1016/j.steroids.2010.01.019. PMID 20138077. S2CID 205253265.
External links
Progestogens (and progestins) |
| ||||
---|---|---|---|---|---|
Antiprogestogens |
| ||||
|
Androgen receptor modulators | |||||||
---|---|---|---|---|---|---|---|
AR |
| ||||||
GPRC6A |
| ||||||
|
Progesterone receptor modulators | |||||||
---|---|---|---|---|---|---|---|
PR |
| ||||||
mPR (PAQR) |
| ||||||
|